Companies › Caravel Oculus
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CA201A (ascorbic acid ophthalmic solution 5%) Antioxidant; reduces corneal endothelial cell loss through free radical scavenging | – | Phase 2 | Corneal Endothelial Cell Loss | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07694375 | CA201A (ascorbic acid ophthalmic solution 5%) | Phase 2 | Corneal Endothelial Cell Loss | Ophthalmology | Jan 2027 |
No annotated target.
–
Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Tavo Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.